-
AN AI-BASED MODEL EXPLAINER TO SUPPORT ONBOARDING AND KNOWLEDGE TRANSFER FOR EXCEL COST-EFFECTIVENESS MODELS
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF PRECISION SCREENING FOR ATRIAL FIBRILLATION: A DECISION-ANALYTIC MODEL
Mar 18, 2026, 21:38 PM -
DEVELOPING AND OPERATIONALIZING A SOCIETAL VALUE FRAMEWORK: A STYLIZED CASE STUDY IN ADVANCED HEPATOCELLULAR CARCINOMA
Mar 18, 2026, 21:38 PM -
COST EFFECTIVENESS ANALYSIS OF ADULT PNEUMOCOCCAL VACCINES INCLUDING PCV21 AND PCV20 TO OPTIMIZE NATIONAL IMMUNIZATION PROGRAM IN JAPAN
Mar 18, 2026, 21:38 PM -
A NOVEL BAYESIAN MODELING APPROACH INCREASES PRECISION OF PREDICTED LONG-TERM DURABILITY OF ETRANACOGENE DEZAPARVOVEC FOR THE TREATMENT OF HEMOPHILIA B
Mar 18, 2026, 21:38 PM -
COMPARATIVE EFFECTIVENESS OF ALPHA BLOCKERS VERSUS ALPHA INHIBITORS USING PATIENT-REPORTED OUTCOMES AMONG ADULT MEN DIAGNOSED WITH BPH IN THE USA USING MEPS DATA (2018-2023)
Mar 18, 2026, 21:38 PM -
FROM NATURAL HISTORY TO POST-APPROVAL EVIDENCE: AN INTEGRATED MULTI-SOURCE REAL-WORLD PROGRAM CHARACTERIZING IGA NEPHROPATHY IN THE ERA OF ORAL TARGETED-RELEASE FORMULATION OF BUDESONIDE
Mar 18, 2026, 21:38 PM -
SUSTAINED FACTOR IX LEVELS AT 5-YEARS AFTER ETRANACOGENE DEZAPARVOVEC - THE EXPONENTIAL DECAY MODEL MAY UNDERESTIMATE OBSERVED RESULTS
Mar 18, 2026, 21:38 PM -
A LIVING NETWORK META-ANALYSIS FRAMEWORK FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CHRONIC VENOUS INSUFFICIENCY TREATMENT
Mar 18, 2026, 21:38 PM -
TRENDS IN BACK PAIN HEALTHCARE UTILIZATION AND EXPENDITURES AMONG U.S. ADULTS: 2007 VS 2023
Mar 18, 2026, 21:38 PM -
INCREASED HEALTHCARE COSTS AND RESOURCE UTILIZATION FOLLOWING PROGRESSION IN PATIENTS WITH HR+/HER2- METASTATIC BREAST CANCER RECEIVING CHEMOTHERAPY
Mar 18, 2026, 21:38 PM -
CAREGIVER-DEFINED UNMET NEEDS TO SUPPORT PATIENT-CENTERED TRIAL DESIGN AND VALUE CONSIDERATIONS IN MULTIPLE SULFATASE DEFICIENCY (MSD)
Mar 18, 2026, 21:38 PM -
STANDARDIZING AN ANNUAL REFERENCE COMPARATOR OF HEALTHCARE UTILIZATION OF PAINFUL DIABETIC NEUROPATHY (PDPN): A U.S. CLAIMS COHORT META-ANALYSIS FOR MODELING AND PAYER BENCHMARKING
Mar 18, 2026, 21:38 PM -
PRICE ANALYSIS OF GENE THERAPIES AUTHORIZED BY THE U.S. FOOD AND DRUG ADMINISTRATION
Mar 18, 2026, 21:38 PM -
FAST-TRACKING RARE DISEASES: USE OF FDA EXPEDITED PATHWAYS FOR ORPHAN DRUGS
Mar 18, 2026, 21:38 PM -
IMPACT OF TIME-VARYING RELAPSE RISK ON LONG-TERM COST-EFFECTIVENESS OUTCOMES IN CHRONIC RELAPSING DISEASES
Mar 18, 2026, 21:38 PM -
HOW HAVE ECONOMIC EVALUATIONS EVALUATED UNCERTAINTY IN POLYGENIC RISK SCORES?: A SCOPING REVIEW
Mar 18, 2026, 21:38 PM -
REAL-WORLD FUNCTIONAL, ECONOMIC, AND BEHAVIORAL BURDEN OF ACUTE GLUTEN EXPOSURE IN U.S. ADULTS WITH CELIAC DISEASE: INSIGHTS FROM A LARGE NATIONAL COHORT
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS ANALYSIS OF SAVOLITINIB VERSUS GLUMETINIB IN THE FIRST-LINE TREATMENT OF CHINESE ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBORING MET EXON 14 SKIPPING MUTATION
Mar 18, 2026, 21:38 PM -
REAL-WORLD IMPACT OF CURRENT TREATMENTS ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN ADULTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP): A SYSTEMATIC LITERATURE REVIEW (SLR)
Mar 18, 2026, 21:38 PM
